The Department of Health (MDH) announced it provided the Prescription Drug Affordability Board (PDAB) with the first list of drugs that meet the statutory criteria for potential cost review. In total, MDH reported that 1,083 prescription drug products met at least one of the statutory criteria—and many drugs met multiple criteria or the same criterion multiple times. The statutory criteria include thresholds for significant price increases (such as price increases exceeding 15% in a year) and expensive drugs (such as prices of more than $60,000 per year or course of treatment). The PDAB was established to conduct cost reviews of prescription drug products and has authority to set payment limits. The Board began its work in 2024 and is comprised of seven voting members appointed by the Governor and two nonvoting legislative members.
To learn more about the PDAB, to attend a public meeting of the PDAB, or to submit comments to the PDAB, please visit the PDAB website. Stakeholders interested in receiving announcements on prescription drug price transparency at MDH may subscribe to Prescription Drug Price Transparency updates.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.